Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 95Terminated 41Active not recruiting 18Recruiting 8Withdrawn 6Unknown 6Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1HTLV-I Infections 1

Interventions

Specimen Handling 15Biopsy 9Cyclophosphamide 8Magnetic Resonance Spectroscopy 7venetoclax 5Etoposide 4Azacitidine 4fludarabine phosphate 3X-Rays 3Tacrolimus 3Paclitaxel 3Interleukin-2 3Carboplatin 3zanubrutinib 2prednylidene 2fludarabine 2durvalumab 2deltacortene 2aldesleukin 2Vincristine 2Rituximab 2Radiotherapy, Intensity-Modulated 2Protein Subunit Vaccines 2Prednisone 2Nivolumab 2Melphalan 2Injections 2Gemcitabine 2E 7107 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Suspended × Lenalidomide × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡